Full text

Turn on search term navigation

© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Amyloidosis is an infiltrative disease that may cause cardiomyopathy if the precursor protein that misfolds and forms the amyloid is transthyretic or plasma abnormal light chains. Transthyretin amyloid cardiomyopathy has to be diagnosed timely and accurately since there are specific treatment options to support the patients. Multimodality imaging including electrocardiography, echocardiography with strain imaging and cardiac magnetic resonance applying late gadolinium enhancement imaging, native T1 mapping and extracellular volume, raise a high suspicion of the disease and bone scintigraphy set the diagnosis even without the need of biopsy. However, the morbidity and mortality remain high and the need for risk stratification and assessment of the response to treatment are of paramount importance. Cardiac imaging biomarkers offer a thoughtful insight into the prognosis of these patients at diagnosis and after treatment. The current narrative review aims to enlighten the use of multimodality cardiac imaging in transthyretic amyloid cardiomyopathy throughout the disease pathogenesis and evolution from diagnosis to prognosis and response to treatment in a personalized manner.

Details

Title
Transthyretin Amyloid Cardiomyopathy: Current Diagnostic Approach and Risk Stratification with Multimodality Imaging
Author
Tziomalos, Georgios 1 ; Zegkos, Thomas 1   VIAFID ORCID Logo  ; Baltagianni, Eleftheria 1 ; Maria-Anna Bazmpani 1   VIAFID ORCID Logo  ; Exadaktylou, Paraskevi 2 ; Parcharidou, Despoina 1 ; Gossios, Thomas 1   VIAFID ORCID Logo  ; Doumas, Argyrios 2 ; Karamitsos, Theodoros 1   VIAFID ORCID Logo  ; Vassilikos, Vassilios 3   VIAFID ORCID Logo  ; Efthimiadis, Georgios 1 ; Ziakas, Antonios 1 ; Kamperidis, Vasileios 1   VIAFID ORCID Logo 

 Department of Cardiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece; [email protected] (G.T.); [email protected] (T.Z.); [email protected] (E.B.); [email protected] (M.-A.B.); [email protected] (D.P.); [email protected] (T.G.); [email protected] (T.K.); [email protected] (G.E.); [email protected] (A.Z.) 
 Laboratory of Nuclear Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece; [email protected] (P.E.); [email protected] (A.D.) 
 Department of Cardiology, Ippokrateio Hospital, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece; [email protected] 
First page
2014
Publication year
2025
Publication date
2025
Publisher
MDPI AG
e-ISSN
20770383
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3181505764
Copyright
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.